Preclinical and clinical data shows its utility as a promising therapeutic option for CRC when used alone or in combination with standard therapies, especially in tumors with PTEN loss or PI3K pathway mutations [68,69]. This evidence concerns the gene PTEN and colorectal carcinoma.